Lenograstim
Recombinant human granulocyte-colony stimulating factor (rhG-CSF)
Also known as: Granocyte · rhG-CSF · Recombinant human granulocyte-colony stimulating factor
Reviewed by the VetSheet Veterinary TeamUpdated Apr 5, 2026Evidence-based veterinary reference
Dosing by species
Dosing data for this drug is not yet available in the VetSheet formulary. Every other section below is complete. Consult the current product label before prescribing.
Overview
Lenograstim is a recombinant human granulocyte-colony stimulating factor (rhG-CSF). It is used to stimulate the production of white blood cells, specifically granulocytes, in the bone marrow.
Clinical Pearl: In veterinary medicine, it is primarily used off-label to treat severe, life-threatening neutropenia associated with chemotherapy, parvovirus infection, or idiopathic neutropenia.
Mechanism of action
Activates proliferation and differentiation of granulocyte progenitor cells → enhances granulopoiesis (production of neutrophils and other granulocytes in the bone marrow).
Safety & warnings
Contraindications
- Known hypersensitivity to G-CSF products
- Myeloid malignancies (unless specifically indicated)
Adverse effects
- Bone pain
- Fever
- Injection site reactions
- Splenomegaly (rare)
- Leukocytosis
Precautions
Warning: Monitor complete blood counts (CBC) regularly to avoid excessive leukocytosis. Use with caution in patients with pre-existing splenic enlargement.
Monitoring
- Complete Blood Count (CBC) with differential
- Neutrophil count
- Body temperature
Pharmacokinetics
Half-life
Absorption
Well absorbed following subcutaneous administration.
Distribution
Distributes primarily to the bone marrow and highly perfused organs.
Metabolism
Degraded by peptides and cleared by neutrophils (receptor-mediated clearance).
Elimination
Renal excretion and neutrophil-mediated clearance.
Overdose
Excessive use may lead to severe leukocytosis. Treatment is supportive and involves discontinuing the drug or reducing the dose until white blood cell counts normalize.
Available products
Formulations
- Injectable: 33.6 million IU (263 μg) vial for reconstitution
Human-labeled
- Granocyte 33.6 million IU (263 μg) vial for reconstitution
Regulatory status
Approved for human use (POM); used off-label in veterinary medicine under the cascade.
Approved for human use (POM); used off-label in veterinary medicine under the cascade.
No regulatory data for: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Storage & stability
Store in a refrigerator (2°C - 8°C). Do not freeze. Reconstituted solutions should be used promptly according to manufacturer instructions.
Client information
Lenograstim is given by injection to help your pet's bone marrow produce more white blood cells, which are essential for fighting infections.
- Administration: Usually given as an injection under the skin.
- Side effects: Your pet may experience mild bone or joint pain, or a slight fever. Contact your veterinarian if your pet seems very uncomfortable.
- Monitoring: Regular blood tests will be needed to ensure the white blood cell count is recovering appropriately without going too high.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.